Progress in small-cell lung cancer: The lowest common denominator

被引：7
作者：
Gandara, David R. [1 ]
Lara, Primo N., Jr. [1 ,2 ]
Natale, Ronald
Belani, Chandra [3 ]
机构：
[1] Univ Calif Davis, Med Ctr, Sacramento, CA 95817 USA
[2] Cedars Sinai Canc Ctr, Los Angeles, CA USA
[3] Penn State Canc Ctr, Hershey, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 26期
关键词：
D O I：
10.1200/JCO.2008.17.2692
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：4236 / 4238
页数：3
相关论文
共 13 条
  • [1] Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter:: A balanced polymorphism for regulation of bilirubin metabolism?
    Beutler, E
    Gelbart, T
    Demina, A
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (14) : 8170 - 8174
  • [2] Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-0897113; Silva Study)
    Giaccone, G
    Debruyne, C
    Felip, E
    Chapman, PB
    Grant, SC
    Millward, M
    Thiberville, L
    D'addario, G
    Coens, C
    Rome, LS
    Zatloukal, P
    Masso, O
    Legrand, C
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (28) : 6854 - 6864
  • [3] Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin
    Han, Ji-Youn
    Lim, Hyeong-Seok
    Shin, Eun Soon
    Yoo, Yeon-Kyeong
    Park, Yong Hoon
    Lee, Jong-Eun
    Jang, In-Jin
    Lee, Doe Ho
    Lee, Jin Soo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (15) : 2237 - 2244
  • [4] Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer
    Hanna, N
    Bunn, PA
    Langer, C
    Einhorn, L
    Guthrie, T
    Beck, T
    Ansar, R
    Ellis, P
    Byrne, M
    Morrison, M
    Hariharan, S
    Wang, B
    Sandler, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (13) : 2038 - 2043
  • [5] Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer:: A Randomized phase III trial
    Hermes, Andreas
    Bergman, Bengt
    Bremnes, Roy
    Ek, Lars
    Fluge, Sverre
    Sederholm, Christer
    Sundstrom, Stein
    Thaning, Lars
    Vilsvik, Jan
    Aasebo, Ulf
    Soerenson, Sverre
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (26) : 4261 - 4267
  • [6] Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan
    Innocenti, F
    Undevia, SD
    Iyer, L
    Chen, PX
    Das, S
    Kocherginsky, M
    Karrison, T
    Janisch, L
    Ramírez, J
    Rudin, CM
    Vokes, EE
    Ratain, MJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (08) : 1382 - 1388
  • [7] LARA P, 2007, J CLIN ONCOL S, V25, pS390
  • [8] NATALE RB, 2008, J CLIN ONCOL, V26, pS400
  • [9] Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and leukemia group B trial 9732
    Niell, HB
    Herndon, JE
    Miller, AA
    Watson, DM
    Sandler, AB
    Kelly, K
    Marks, RS
    Perry, MC
    Ansari, RH
    Otterson, G
    Ellerton, J
    Vokes, EE
    Green, MR
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 3752 - 3759
  • [10] Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer
    Noda, W
    Nishiwaki, Y
    Kawahara, M
    Negoro, S
    Sugiura, T
    Yokoyama, A
    Fukuoka, M
    Mori, K
    Watanabe, K
    Tamura, T
    Yamamoto, S
    Saijo, N
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (02) : 85 - 91
12